Aldose Reductase (AKR1B1) Antibody (HRP)
169€ (20 µg)
Por favor contáctenos para obtener información detallada sobre el precio y disponibilidad.
935106861
info@markelab.com
name
Aldose Reductase (AKR1B1) Antibody (HRP)
category
Primary Antibodies
provider
Abbexa
reference
abx314044
tested applications
ELISA
Description
AKR1B1 Antibody (HRP) is a Rabbit Polyclonal against AKR1B1 conjugated to HRP.
Documents del producto
Instrucciones
Data sheet
Product specifications
| Category | Primary Antibodies |
| Immunogen Target | Aldose Reductase (AKR1B1) |
| Host | Rabbit |
| Reactivity | Human |
| Recommended Dilution | Optimal dilutions/concentrations should be determined by the end user. |
| Clonality | Polyclonal |
| Conjugation | HRP |
| Isotype | IgG |
| Purity | > 95% |
| Purification | Purified by Protein G. |
| Size 1 | 20 µg |
| Size 2 | 50 µg |
| Size 3 | 100 µg |
| Size 4 | 200 µg |
| Size 5 | 1 mg |
| Form | Liquid |
| Tested Applications | ELISA |
| Buffer | 0.01 M PBS, pH 7.4, 0.03% Proclin-300 and 50% Glycerol. |
| Availability | Shipped within 5-10 working days. |
| Storage | Aliquot and store at -20°C. Avoid exposure to light. Avoid repeated freeze/thaw cycles. |
| Dry Ice | No |
| UniProt ID | P15121 |
| Gene ID | 231 |
| NCBI Accession | NP_001619.1 |
| OMIM | 103880 |
| Alias | AKR1B1,ADR ALDR1,ALR2,AR |
| Background | Antibody anti-AKR1B1 |
| Status | RUO |
Descripción
AKR1B1, also known as aldose reductase, is a key enzyme in the polyol pathway that converts glucose to sorbitol under hyperglycemic conditions. It has a significant role in the pathogenesis of diabetic complications, such as neuropathy, nephropathy, and retinopathy, as sorbitol accumulation induces osmotic stress and oxidative damage. AKR1B1 also metabolizes reactive aldehydes, including lipid peroxidation products like 4-hydroxynonenal (4-HNE), contributing to cellular detoxification under oxidative stress. Its overactivation under diabetic and inflammatory conditions exacerbates oxidative stress and inflammatory signaling pathways. AKR1B1 inhibitors have been developed as potential therapeutic agents for managing diabetic complications. Beyond diabetes, AKR1B1 is involved in steroid metabolism and the detoxification of xenobiotics. It has also been implicated in cancer progression, as its expression is upregulated in some tumors, promoting proliferation and chemoresistance by reducing reactive aldehydes and maintaining cellular redox balance.
Related Products
Human AKR1B1(Aldose reductase) ELISA Kit
Ver Producto
Mouse Akr1b1(Aldose reductase) ELISA Kit
Ver Producto